Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. How I treat NTRK gene fusion-positive cancers

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Hallmarks of glioblastoma: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. The European Cancer Patient's Bill of Rights, update and implementation 2016

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Whole genome sequencing of breast cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Subtypes in BRCA-mutated breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Endocrine therapy constitutes a central modality in the treatment of oestrogen receptor (ER)-positive advanced breast cancer.

PURPOSE: To evaluate the evidence for endocrine treatment in postmenopausal patients with advanced breast cancer focusing on the aromatase inhibitors, letrozole, anastrozole, exemestane and fulvestrant.

METHODS: A review was carried out using PubMed. Randomised phase II and III trials reporting on ≥100 patients were included.

RESULTS: 35 trials met the inclusion criteria. If not used in the adjuvant setting, a non-steroid aromatase inhibitor was the optimal first-line option. In general, the efficacy of the different aromatase inhibitors and fulvestrant was similar in tamoxifen-refractory patients. A randomised phase II trial of palbociclib plus letrozole versus letrozole alone showed significantly increased progression-free survival (PFS) when compared with endocrine therapy alone in the first-line setting (20.2 vs 10.2 months). Furthermore, the addition of everolimus to exemestane in the Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) study resulted in an extension of median PFS by 4.5 months after recurrence/progression on a non-steroid aromatase inhibitor. However, overall survival was not significantly increased.

CONCLUSION: Conventional treatment with an aromatase inhibitor or fulvestrant may be an adequate treatment option for most patients with hormone receptor-positive advanced breast cancer. Mammalian target of rapamycin (mTOR) inhibition and cyclin-dependent kinase 4/6 (CDK4/6) inhibition might represent substantial advances for selected patients in some specific settings. However, there is an urgent need for prospective biomarker-driven trials to identify patients for whom these treatments are cost-effective.

OriginalsprogEngelsk
TidsskriftESMO Open
Vol/bind1
Udgave nummer4
Sider (fra-til)e000062
ISSN2059-7029
DOI
StatusUdgivet - 2016

ID: 49699221